Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-506 and midazolam drug-drug interaction study in healthy male subjects
NL-OMON51608Phase 1Completed
- Sponsor
- Chong Kun Dang Pharmaceutical
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CKD-506 and midazolam in idiopathic pulmonary fibrosis (IPF), sponsored by Chong Kun Dang Pharmaceutical. Primary endpoint: Effect of CKD-506 on midazolam pharmacokinetics. Started Feb 2022; status: completed.
02
Drugs
CKD-506midazolam
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON51608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51608.